Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Coolief Cooled Radiofrequency vs. Conventional Radiofrequency to Manage OA Knee Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04145011
Recruitment Status : Recruiting
First Posted : October 30, 2019
Last Update Posted : December 4, 2019
Sponsor:
Information provided by (Responsible Party):
Avanos Medical

Tracking Information
First Submitted Date  ICMJE October 28, 2019
First Posted Date  ICMJE October 30, 2019
Last Update Posted Date December 4, 2019
Actual Study Start Date  ICMJE October 4, 2019
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 28, 2019)
Numeric Rating Scale (NRS) [ Time Frame: 12 months ]
The proportion of subjects whose knee pain is reduced by ≥ 50% based on the NRS. The NRS is an 11-point scale (0 points to 10 points), where 0 points equals "no pain" and 10 points equals "worst pain". There are no sub-scales.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT04145011 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: October 28, 2019)
  • Additional Interventions [ Time Frame: 12 months ]
    The proportion of subjects requiring additional intervention for their OA knee pain.
  • Knee injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS, JR) [ Time Frame: 12 months ]
    The change in KOOS JR score from baseline. The KOOS JR is a short form of the KOOS that assesses patient stiffness (1 item), pain (4 items), and functions of daily living (2 items). Scores range from 0 to 100 with a score of 0 indicating total knee disability and 100 indicating perfect knee health.
  • EQ-5D-5L [ Time Frame: 12 months ]
    The change in measured EQ-5D-5L scale from baseline. This outcome instrument is composed of five sub-scales containing five questions each. The point range for each sub-scale is from 1 to 5, with "1" indicating the best study subject condition and "5" indicating the worst study subject condition. Thus, the minimum and maximum scores per sub-scale are 1 and 5, respectively, and such scores for the entire instrument are 5 (best study subject condition) and 25 (worst study subject condition). The sub-scale topics are: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression
  • Global Perceived Effect (GPE) [ Time Frame: 12 months ]
    The measured Global Perceived Effect scale. The Global Perceived Effect is a 7-point scale: 1 point = "worst ever", 2 points = "much worse", 3 points = "worse", 4 points = "not improved but not worse", 5 points = "improved", 6 points = "much improved", 7 points = "best ever". There are no sub-scales.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: October 28, 2019)
  • Numeric Rating Scale (NRS) [ Time Frame: 24 months ]
    The proportion of subjects whose knee pain is reduced by ≥ 50% based on the NRS. The NRS is an 11-point scale (0 points to 10 points), where 0 points equals "no pain" and 10 points equals "worst pain". There are no sub-scales.
  • Additional Interventions [ Time Frame: 24 months ]
    The proportion of subjects requiring additional intervention for their OA knee pain.
  • Knee injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS, JR) [ Time Frame: 24 months ]
    The change in KOOS JR score from baseline. The KOOS JR is a short form of the KOOS that assesses patient stiffness (1 item), pain (4 items), and functions of daily living (2 items). Scores range from 0 to 100 with a score of 0 indicating total knee disability and 100 indicating perfect knee health.
  • EQ-5D-5L [ Time Frame: 24 months ]
    The change in measured EQ-5D-5L scale from baseline. This outcome instrument is composed of five sub-scales containing five questions each. The point range for each sub-scale is from 1 to 5, with "1" indicating the best study subject condition and "5" indicating the worst study subject condition. Thus, the minimum and maximum scores per sub-scale are 1 and 5, respectively, and such scores for the entire instrument are 5 (best study subject condition) and 25 (worst study subject condition). The sub-scale topics are: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression
  • Global Perceived Effect (GPE) [ Time Frame: 24 months ]
    The measured Global Perceived Effect scale. The Global Perceived Effect is a 7-point scale: 1 point = "worst ever", 2 points = "much worse", 3 points = "worse", 4 points = "not improved but not worse", 5 points = "improved", 6 points = "much improved", 7 points = "best ever". There are no sub-scales.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Coolief Cooled Radiofrequency vs. Conventional Radiofrequency to Manage OA Knee Pain
Official Title  ICMJE A Prospective, Multi-center, Randomized, Single Blind Clinical Trial Comparing COOLIEF* Cooled Radiofrequency to Conventional Radiofrequency Ablation of the Genicular Nerves in the Management of Knee Pain in an Osteoarthritic Patient Population
Brief Summary This study is being performed to assess the relative effectiveness of genicular nerve ablation with the COOLIEF* Cooled Radiofrequency probe to manage moderate to severe knee pain in patients with osteoarthritis (OA) of the knee when compared to radiofrequency ablation using a Standard Radiofrequency probe.
Detailed Description This is a prospective, multi-center, randomized, single-blind comparison study examining the outcomes of subjects with osteoarthritic knee pain undergoing a procedure to create a radiofrequency lesion of the genicular nerves with either Cooled Radiofrequency Ablation (CRFA) or Conventional (Standard) Radiofrequency Ablation (SRFA). Approximately 148 participants from up to 15 sites will be enrolled into this study, with subjects undergoing either CRFA or SRFA in a 1:1 randomization scheme. Follow-up will be conducted for 24 months post-treatment, with the primary endpoint being completed at month 12. Pain, overall outcome, quality of life, pain medication use, and adverse events will be compared between the two treatment groups to determine success.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Masking Description:
The study is a participant-blinded trial and deliberate action, utilizing a physical barrier, will be needed to ensure the blind remains intact.
Primary Purpose: Treatment
Condition  ICMJE Osteoarthritis of the Knee
Intervention  ICMJE
  • Device: Cooled Radiofrequency
    Delivery of energy to ablate sensory nerves via cooled radiofrequency probe (18g, 4mm active tip)
    Other Name: Coolief, CRFA
  • Device: Standard Radiofrequency
    Delivery of energy to ablate sensory nerves via non-cooled standard radiofrequency probe (22g, curved 10mm active tip)
    Other Name: Conventional Radiofrequency, SRFA
Study Arms  ICMJE
  • Experimental: COOLIEF Cooled Radiofrequency Probe
    Cooled radiofrequency energy will be delivered to the study subjects' knee to ablate culprit sensory nerves and reduce knee pain
    Intervention: Device: Cooled Radiofrequency
  • Active Comparator: Conventional (Standard) Radiofrequency Probe
    Standard (non-cooled) radiofrequency energy will be delivered to the study subjects' knee to ablate culprit sensory nerves and reduce knee pain
    Intervention: Device: Standard Radiofrequency
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 28, 2019)
148
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2022
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Age ≥ 21 years
  2. Able to understand and personally sign and date the informed consent form
  3. Able to complete outcome measures
  4. Chronic knee pain for longer than 6 months that interferes with functional activities (for example, ambulation, prolonged standing, etc.)
  5. Continued pain in the target knee despite at least 3 months of conservative treatments, including activity modification, home exercise, protective weight bearing, and/or analgesics (for example, acetaminophen or non-steroidal anti-inflammatory drugs [NSAIDs])
  6. Positive response (defined as a decrease in numeric pain scores of at least 50%) to a single genicular nerve block of the index knee
  7. Pain on NRS ≥ 6 on an 11-point scale for the index knee
  8. Radiologic confirmation of osteoarthritis (x-ray/MRI/CT) grade 2 (mild), 3 (moderate) or 4 (severe) noted within 6 months for the index knee
  9. Analgesics including membrane stabilizers such as Neurontin (gabapentin) and antidepressants for pain, such as Cymbalta (duloxetine), must be clinically stable (defined as stable dosage for ≥ 6 weeks prior to the screening visit) and shall not change during the course of the study without approval of the investigator
  10. Agree to see one physician (study physician) for knee pain during the study period
  11. Subjects of child bearing potential must be willing to utilize double barrier contraceptive method
  12. Willingness to comply with the requirements of this protocol for the full duration of the study (24 months regardless of effect of initial therapy)

Exclusion Criteria:

  1. Evidence of inflammatory arthritis (example, rheumatoid arthritis) or other systemic inflammatory condition (example; gout, fibromyalgia, MS, Lupus, etc.) that could cause knee pain
  2. Evidence of neuropathic pain affecting the index knee
  3. Previous or pending lower limb amputation
  4. Intra-articular steroid injection into the index knee within 90 days from randomization
  5. Hyaluronic acid injection, platelet rich plasma (PRP), stem cell, or arthroscopic debridement/lavage injection into the index knee within 180 days from randomization
  6. Prior radiofrequency ablation of the genicular nerves of the index knee
  7. Prior partial, resurfacing, or total knee arthroplasty of the index knee (residual hardware)
  8. Clinically significant ligamentous laxity of the index knee
  9. Clinically significant valgus/varus deformities or evidence of pathology (other than osteoarthritis of knee) that materially affects gait or function of the knee or is the underlying cause of the knee pain and/or functional limitations
  10. Body mass index (BMI) > 40 kg/m2
  11. Extremely thin patients and those with minimal subcutaneous tissue thickness that would not accommodate a radiofrequency lesion of up to 14 mm in diameter to limit the risk of skin burns
  12. Pending or active compensation claim, litigation, or disability remuneration (secondary gain)
  13. Pregnant, nursing or intent of becoming pregnant during the study period
  14. Chronic pain associated with significant psychosocial dysfunction
  15. Poorly controlled severe psychiatric illness or ongoing psychological barriers to recovery, as determined by the investigator
  16. Allergies to any of the medications to be used during the procedures
  17. Active joint infection or systemic or localized infection at needle entry sites (subject may be considered for inclusion once infection is resolved)
  18. History of uncontrolled coagulopathy, ongoing coagulation treatment that cannot be safely interrupted for procedure, or unexplained or uncontrollable bleeding that is uncorrectable
  19. Identifiable anatomical variability that would materially alter the procedure as described in the protocol
  20. Within the preceding 2 years, subject has suffered from active narcotic addiction, substance, or alcohol abuse
  21. Current prescribed opioid medications greater than 60 mg morphine equivalent daily opioid dose
  22. Uncontrolled immunosuppression (e.g. AIDS, cancer, diabetes, etc.)
  23. Subject currently implanted with pacemaker, stimulator or defibrillator
  24. Participating in another clinical trial/investigation which included therapeutic treatment within 30 days prior to signing informed consent
  25. Subject unwilling or unable to comply with follow up schedule, protocol requirements or procedures
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 21 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: William Keck, BS 470-448-5509 William.Keck@avanos.com
Contact: David Curd, MS 470-448-5178 David.Curd@avanos.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04145011
Other Study ID Numbers  ICMJE 105-18-0002
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Avanos Medical
Study Sponsor  ICMJE Avanos Medical
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: David Kennedy, MD Vanderbilt Stallworth Rehabilitation Hospital
PRS Account Avanos Medical
Verification Date December 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP